A powerful experimental weight-loss drug has been shown to substantially reduce knee pain in patients suffering from osteoarthritis, according to newly released clinical trial findings. Participants receiving the highest dose of retatrutide lost approximately 25 percent of their body weight, while roughly two-thirds reported at least a 50 percent reduction in knee pain. The results suggest the drug could offer a significant new option for millions of people worldwide living with painful knee arthritis, a condition currently managed largely through pain relief medication, physical therapy, and joint replacement surgery.
Researchers caution, however, that the drug's ability to prevent further structural damage to the joint remains unknown, leaving open questions about its long-term disease-modifying potential. Retatrutide, which targets multiple hormone receptors involved in appetite and metabolism, has drawn considerable attention amid a broader surge of interest in weight-loss medications. The findings add to a growing body of evidence linking significant weight reduction to improved outcomes for osteoarthritis patients, though experts say larger and longer studies are needed before the treatment could reach regulatory approval.
Independent reporting synthesized from primary wires and global correspondents.